Trump’s FDA Chief Resigns After Clashes with Industry and Activists
Dr. Marty Makary, the surgeon and health researcher serving as the Food and Drug Administration’s commissioner under President Donald Trump, has resigned amid mounting pressure from pharmaceutical executives, vaping lobbyists, and anti-abortion activists—all of whom had publicly criticized his tenure. The departure marks the fourth high-profile resignation in the Trump administration this year and raises questions about the stability of the FDA’s leadership as the 2028 election cycle approaches.
Who Is Dr. Marty Makary?
Makary, a professor of surgery at Johns Hopkins University and a vocal critic of what he described as “corporate influence” in healthcare, was appointed to the FDA in 2025 after serving as a senior advisor to Trump during his first term. His tenure was marked by clashes with multiple stakeholders, including:
- Pharmaceutical CEOs: Makary had publicly questioned the FDA’s approval process for new drugs, arguing that financial conflicts of interest among regulators compromised patient safety. His critiques drew sharp rebuke from industry leaders, who accused him of undermining innovation.
- Vaping Lobbyists: His push for stricter regulations on e-cigarettes and flavored vaping products alienated lobbyists tied to the tobacco industry, who had previously enjoyed favorable treatment under the Trump administration.
- Anti-Abortion Groups: Makary’s refusal to fast-track emergency authorizations for abortion-related medications—despite pressure from conservative allies—further strained his relationships with key Trump supporters.
Sources close to the White House confirmed Makary’s resignation in a statement to AP News, though no official reason was provided beyond “personal and professional considerations.”
Why This Resignation Matters
The FDA’s leadership vacuum comes at a critical juncture. With the Trump administration facing scrutiny over its handling of public health crises—including ongoing debates over drug pricing, vaccine mandates, and emerging biotech therapies—the departure of Makary could:
1. Disrupt Regulatory Priorities
Makary’s resignation leaves the FDA without a permanent commissioner just as the agency grapples with:
- Accelerated approvals for emerging treatments for chronic diseases like Alzheimer’s and diabetes.
- Ongoing litigation over AI-driven medical devices, where the FDA’s stance has been inconsistent.
- Pressure to streamline generic drug approvals amid shortages of critical medications.
2. Weaken Trump’s Health Policy Agenda
Makary’s resignation follows a pattern of high-profile departures from the Trump administration in 2026, including:
- The resignation of Kevin Warsh, Trump’s Federal Reserve nominee, amid Senate confirmation battles.
- Reports of internal dissent within the CDC over politicized public health messaging.
Analysts suggest the exodus reflects broader tensions between Trump’s base and his administration’s attempts to balance industry deregulation with regulatory oversight.
3. Impact the 2028 Election Narrative
With Trump floating potential 2028 running mates like Sen. Marco Rubio (R-FL) or Vice President JD Vance, the FDA’s instability could become a campaign liability. Critics may seize on the resignations to argue that Trump’s administration is:
- Unable to retain competent leadership.
- Prioritizing political appeasement over scientific expertise.
- Ill-equipped to handle future health crises.
What Happens Next?
The White House has not yet named a replacement for Makary. Options under consideration include:
- Acting Commissioner Robert Califf: The former FDA chief, now a senior advisor, has been floated as a potential interim leader. Califf, a cardiologist with deep industry ties, would likely take a more conciliatory approach with pharmaceutical firms.
- Political Appointee: A loyalist from Trump’s inner circle, such as HHS Secretary Xavier Becerra’s deputy, could be fast-tracked to fill the role, though confirmation battles loom.
- Bipartisan Nomination: A compromise candidate with bipartisan appeal—such as a former Substantial Pharma executive or a academic researcher—might be pursued to stabilize the agency ahead of the 2026 midterms.
In the meantime, the FDA’s day-to-day operations will likely be overseen by deputy commissioners, though major policy decisions may stall until a permanent leader is confirmed.
FAQ: Your Questions Answered
Will this resignation delay drug approvals?
Unlikely in the short term, as the FDA has established protocols for acting commissioners. However, high-profile decisions—such as approvals for novel therapies—may face delays if political infighting persists.
Could this hurt Trump’s re-election chances?
Potentially. Polling suggests voters prioritize healthcare stability over partisan loyalty. If the FDA’s leadership crisis drags on, it could fuel narratives of administrative chaos—especially in battleground states like Pennsylvania and Michigan, where drug pricing is a key issue.
What was Makary’s biggest policy win?
Makary’s most notable achievement was accelerating reviews for medications used in medication-assisted treatment (MAT) for opioid addiction—a rare area of bipartisan agreement. However, his push for transparency in clinical trials drew fierce opposition from drugmakers.
Looking Ahead: What’s Next for the FDA?
As the Trump administration navigates its second term, the FDA’s future hinges on three key factors:
- Political Appointments: Will Trump prioritize loyalty over expertise in filling the commissioner role, or will he seek a unifying figure to quiet criticism?
- Industry Pressure: Pharmaceutical lobbies have already signaled they will push for faster approvals and reduced oversight. Can the FDA resist?
- Public Trust: With misinformation about drugs and vaccines still rampant, the FDA’s credibility will be tested as it grapples with emerging health threats, including potential updates to COVID-19 boosters.
One thing is clear: The resignation of Dr. Makary is not just a personnel change—it’s a symptom of deeper fractures within the Trump administration’s approach to healthcare policy.